Promoter hypermethylation identifies progression risk in bladder cancer.

Promoter hypermethylation identifies progression risk in bladder cancer.

PURPOSE: New methods to accurately predict an individual tumor behavior are urgently required to improve the treatment of cancer. We previously found that promoter hypermethylation can be an accurate predictor of bladder cancer progression, but it is not cancer specific. Here, we investigate a pane...

Podrobná bibliografie
Hlavní autoři:	Yates, DR, Rehman, I, Abbod, M, Meuth, M, Cross, S, Linkens, D, Hamdy, F, Catto, J
Médium:	Journal article
Jazyk:	English
Vydáno:	2007

Podobné jednotky

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
Autor: Yates, DR, a další
Vydáno: (2006)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
Autor: Rouprêt, M, a další
Vydáno: (2008)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
Autor: Roupret, M, a další
Vydáno: (2008)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
Autor: Catto, J, a další
Vydáno: (2007)

Comparative study of intelligent models for the prediction of bladder cancer progression.
Autor: Abbod, M, a další
Vydáno: (2006)

Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
Autor: Catto, J, a další
Vydáno: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
Autor: Yates, DR, a další
Vydáno: (2005)

Artificial intelligence for the prediction bladder cancer
Autor: Abbod, M, a další
Vydáno: (2004)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Autor: Catto, J, a další
Vydáno: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
Autor: Yates, DR, a další
Vydáno: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
Autor: Leiblich, A, a další
Vydáno: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer
Autor: Catto, J, a další
Vydáno: (2006)

Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression
Autor: Wild, P, a další
Vydáno: (2007)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Autor: Catto, J, a další
Vydáno: (2009)

The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
Autor: Catto, J, a další
Vydáno: (2010)

Predictive modeling in cancer: where systems biology meets the stock market.
Autor: Abbod, M, a další
Vydáno: (2009)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
Autor: Catto, J, a další
Vydáno: (2003)

Application of artificial intelligence to the management of urological cancer
Autor: Abbod, MF, a další
Vydáno: (2007)

Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression
Autor: Catto, J, a další
Vydáno: (2007)

Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder
Autor: Yates, D, a další
Vydáno: (2005)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
Autor: Abbod, M, a další
Vydáno: (2006)

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas
Autor: Ahmad, M, a další
Vydáno: (2003)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
Autor: Abbod, M, a další
Vydáno: (2006)

Artificial intelligence and bladder cancer arrays.
Autor: Wild, P, a další
Vydáno: (2007)

Genetic instability and transitional cell carcinoma of the bladder.
Autor: Catto, J, a další
Vydáno: (2004)

Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.
Autor: Dudziec, E, a další
Vydáno: (2011)

PER3 promoter hypermethylation correlates to the progression of pan-cancer
Autor: Yaoxu Li, a další
Vydáno: (2024-10-01)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
Autor: Catto, J, a další
Vydáno: (2003)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
Autor: Rehman, I, a další
Vydáno: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
Autor: Glen, A, a další
Vydáno: (2008)

Inactivation of the hypermethylated in cancer 1 tumour suppressor – not just a question of promoter hypermethylation?
Autor: M Jenal, a další
Vydáno: (2010-10-01)

Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients
Autor: Junhua Luo, a další
Vydáno: (2021-10-01)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Autor: Dhawan, D, a další
Vydáno: (2006)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Autor: Rehman, I, a další
Vydáno: (2004)

Hypermethylation at 45S rDNA promoter in cancers.
Autor: Trang Thi Quynh Tran, a další
Vydáno: (2025-01-01)

Hypermethylation at 45S rDNA promoter in cancers
Autor: Trang Thi Quynh Tran, a další
Vydáno: (2025-01-01)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
Autor: Catto, J, a další
Vydáno: (2006)

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
Autor: Mansukhani Mahesh, a další
Vydáno: (2006-05-01)

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.
Autor: Catto, J, a další
Vydáno: (2010)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
Autor: van Oers, J, a další
Vydáno: (2009)